Free Trial
→ Today's free pick (on me) (From Behind the Markets) (Ad)tc pixel
OTCMKTS:EFTR

eFFECTOR Therapeutics Q3 2023 Earnings Results & Report

eFFECTOR Therapeutics logo
$0.0008 0.00 (0.00%)
As of 11/9/2026

eFFECTOR Therapeutics met analyst earnings expectations in its Q3 2023 results, released November 13, 2023. The company reported EPS of -$3.25 versus the -$3.25 consensus estimate.

Research:Profile

Earnings Announcement Details

Quarter
Q3 2023
Report Date

eFFECTOR Therapeutics EPS Results

Actual EPS
-$3.25
Consensus EPS
-$3.25
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

eFFECTOR Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

eFFECTOR Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

eFFECTOR Therapeutics Q3 2023 Earnings FAQ

eFFECTOR Therapeutics (OTCMKTS:EFTR) reported earnings of -$3.25 per share for Q3 2023, matching the consensus estimate of -$3.25. The report was announced on Monday, November 13, 2023.

eFFECTOR Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for eFFECTOR Therapeutics on the company's earnings history page.

eFFECTOR Therapeutics Earnings Headlines

EFTR - eFFECTOR Therapeutics, Inc.
September 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/EFTR
eFFECTOR Therapeutics (OTC:EFTR) Stock, Insider Trading Activity
October 5, 2024  |  benzinga.comhttps://www.benzinga.com/quote/EFTR/insider-trades
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
July 15, 2024  |  investorplace.comhttps://investorplace.com/2024/07/3-publicly-traded-companies-filing-for-bankruptcy-as-july-kicks-off/
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
June 24, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/24/2902850/0/en/effector-therapeutics-announces-it-will-wind-down-operations-as-it-seeks-strategic-alternatives-and-expects-to-be-delisted-from-nasdaq.html
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
May 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/20/2884841/0/en/effector-therapeutics-to-collaborate-with-the-dana-farber-cancer-institute-on-an-investigator-sponsored-phase-2-clinical-trial-evaluating-zotatifin-as-combination-treatment-in-er-e.html
See More eFFECTOR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like eFFECTOR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on eFFECTOR Therapeutics and other key companies, straight to your email.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics (OTCMKTS:EFTR) is a clinical-stage biopharmaceutical company focused on developing medicines that regulate protein production within cancer cells. Its approach, known as translation control, is designed to interfere with the mechanisms cancer cells use to produce proteins needed for growth, survival and resistance to treatment.

The company’s investigational pipeline has included zotatifin (eFT226), an inhibitor of the eukaryotic initiation factor 4A (eIF4A), and tomivosertib (eFT508), an inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2). These programs have been studied as potential treatments for solid tumors and other cancers, both as standalone therapies and in combination with existing treatments.

Founded in 2012 and headquartered in San Diego, California, eFFECTOR has operated primarily as a research and development company serving the oncology biopharmaceutical market. The company was led by co-founder Steven A. Worland, who has served as president and chief executive officer. Its therapies remain investigational and are subject to clinical development and regulatory review.

View eFFECTOR Therapeutics Profile
Earnings Tools